Abeona Therapeutics Inc EPS Q/Q
Mi az Abeona Therapeutics Inc EPS Q/Q?
A EPS Q/Q az Abeona Therapeutics Inc - -15.43%
Mi a EPS Q/Q meghatározása?
A negyedévenkénti EPS negyedéves növekedési ráta az elmúlt 4 negyedévben a vállalat EPS-jének növekedése az előző 4 negyedév teljesítményéhez képest.
The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS Q/Q a Health Care szektor a NASDAQ-on cégekben a Abeona Therapeutics Inc -hoz képest
Mit csinál Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
eps q/q -hoz hasonló cégek Abeona Therapeutics Inc
- Metlife Inc nak EPS Q/Q -15.61% van
- EyePoint Pharmaceuticals Inc nak EPS Q/Q -15.52% van
- Motus GI Inc nak EPS Q/Q -15.50% van
- Evoke Pharma Inc nak EPS Q/Q -15.48% van
- ageas SA/NV nak EPS Q/Q -15.46% van
- Mohawk Industries nak EPS Q/Q -15.44% van
- Abeona Therapeutics Inc nak EPS Q/Q -15.43% van
- Travelers Companies nak EPS Q/Q -15.38% van
- Marker Therapeutics nak EPS Q/Q -15.38% van
- Theratechnologies nak EPS Q/Q -15.38% van
- Niu Technologies nak EPS Q/Q -15.38% van
- First National (Ontario) nak EPS Q/Q -15.38% van
- Coupa Software Inc nak EPS Q/Q -15.38% van